Senseonics Holdings, Inc., a medical technology company, designs, develops, and commercializes continuous glucose monitoring (CGM) systems for people with diabetes primarily in Europe. Its products include Eversense and Eversense XL, which are implantable CGM systems that is designed to continually and accurately measure glucose levels in people with diabetes for a period of up to 90 and 180 days. The company has a research and development license agreement with TypeZero Technologies, Inc. and Roche Diabetes Care, Inc. to develop a closed loop diabetes management system that allow users to automatically maintain tight glucose control while avoiding hypoglycemia. Senseonics Holdings, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.
Industry, Sector and Symbol
Industry Diagnostics & Research
Sub-IndustryN/A
SectorMedical
Phone+1-301-5157260
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees94
OptionableOptionable
Senseonics (NYSEAMERICAN:SENS) Frequently Asked Questions
What is Senseonics' stock symbol?
Senseonics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "SENS."
How were Senseonics' earnings last quarter?
Senseonics Holdings Inc (NYSEAMERICAN:SENS) released its quarterly earnings results on Thursday, November, 8th. The company reported ($0.14) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.15) by $0.01. The firm had revenue of $5.16 million for the quarter, compared to analysts' expectations of $5.16 million. The firm's quarterly revenue was up 145.7% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.13) EPS. View Senseonics' Earnings History.
When is Senseonics' next earnings date?
What price target have analysts set for SENS?
7 analysts have issued 12-month target prices for Senseonics' stock. Their forecasts range from $5.00 to $7.00. On average, they expect Senseonics' share price to reach $6.00 in the next twelve months. This suggests a possible upside of 121.4% from the stock's current price. View Analyst Price Targets for Senseonics.
What is the consensus analysts' recommendation for Senseonics?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Senseonics in the last year. There are currently 1 sell rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Senseonics.
What are Wall Street analysts saying about Senseonics stock?
Here are some recent quotes from research analysts about Senseonics stock:
- 1. BTIG Research analysts commented, "Senseonics’ reported Q2 sales relatively in line with our estimates and Street expectations. That put the focus squarely on observations from the first days of US launch. Early feedback points to doctors quickly becoming comfortable with the procedure and patients enjoying a long-lasting sensor. Additionally, revenue guidance for 2018 was increased by $1M because of additional confidence in both Europe and the US. We see this as a positive following FDA approval. In our view, the only factor hindering US patient and clinician appetite for Eversense is the timing of payor coverage, which we see as an issue of when, not if. We continue to model 2018 sales slightly above the guidance range. Although SENS shares have been weak since the company’s recent financing, we think shares may trade flat to slightly up Thursday with mgmt raising expectations a bit." (8/9/2018)
- 2. Canaccord Genuity analysts commented, "We maintain our BUY rating on SENS following the FDA’s scheduling of an advisory committee (adcom panel) meeting to review Senseonics’ Eversense. The meeting is scheduled for Thursday, March 29, and comes just in time to meet management’s guidance for a Q1/18 event. As a reminder, management has guided to a US regulatory approval and commercial launch ~2 months after the adcom panel, positioning the company for a late Q2/18 launch – but we model for first US revenues in the Q3/18. We expect trading activity to increase in coming weeks in anticipation of the event, which we believe will be positive given the strong safety and efficacy data from its pivotal trial. Investment highlights The FDA announced that the Clinical Chemistry and Clinical Toxicology Devices Panel will review and make recommendations on Senseonics’ Eversense PMA submission. The adcom panel is scheduled for Thursday, March 29, 2018 and will be held in Washington DC." (3/2/2018)
Has Senseonics been receiving favorable news coverage?
Press coverage about SENS stock has trended somewhat positive on Wednesday, InfoTrie Sentiment reports. The research group ranks the sentiment of news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Senseonics earned a news sentiment score of 1.0 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the next several days.
Are investors shorting Senseonics?
Senseonics saw a decline in short interest during the month of December. As of December 31st, there was short interest totalling 25,165,859 shares, a decline of 5.3% from the December 14th total of 26,580,670 shares. Based on an average daily volume of 1,514,190 shares, the short-interest ratio is presently 16.6 days. Approximately 27.7% of the company's stock are short sold. View Senseonics' Current Options Chain.
Who are some of Senseonics' key competitors?
Some companies that are related to Senseonics include 3D Signatures (DXD), BioNano Genomics (BNGOU), Cambridge Cognition (COG), Carl Data Solutions (CRL), Carl Zeiss Meditec (AFX), Co-Diagnostics (CODX), Deepmatter Group (DMTR), Dorsavi (DVL), EPIGENOMICS AG/S (EPGNY), Eternity Healthcare (ETAH), Genedrive (GDR), GeneNews (GEN), Imaging Dynamics (IDL), LED Medical Diagnostics (LMD) and Lexagene (LXG).
Who are Senseonics' key executives?
Senseonics' management team includes the folowing people:
- Dr. Timothy T. Goodnow, Pres, CEO & Director (Age 57)
- Mr. R. Don Elsey, CFO, Sec. & Treasurer (Age 65)
- Dr. Mukul Jain, Chief Operating Officer (Age 46)
- Ms. Mirasol G. Panlilio, VP & Gen. Mang. of Global Commercial Operations (Age 54)
- Dr. Abhi Chavan Ph.D., VP of Engineering and R&D
Who are Senseonics' major shareholders?
Senseonics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Nisa Investment Advisors LLC (0.01%). Company insiders that own Senseonics stock include Douglas A Roeder, Enterprise Associates 10 L New, Mukul Jain and Peter J Barris. View Institutional Ownership Trends for Senseonics.
Which institutional investors are buying Senseonics stock?
How do I buy shares of Senseonics?
Shares of SENS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Senseonics' stock price today?
One share of SENS stock can currently be purchased for approximately $2.71.
How big of a company is Senseonics?
Senseonics has a market capitalization of $479.26 million. Senseonics employs 94 workers across the globe.
What is Senseonics' official website?
How can I contact Senseonics?
Senseonics' mailing address is 20451 Seneca Meadows Pkwy, GERMANTOWN, MD 20876-7005, United States. The company can be reached via phone at +1-301-5157260.
MarketBeat Community Rating for Senseonics (NYSEAMERICAN SENS)
MarketBeat's community ratings are surveys of what our community members think about Senseonics and other stocks. Vote "Outperform" if you believe SENS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SENS will underperform the S&P 500 over the long term. You may vote once every thirty days.
